Skip to content
OpenCapital
Get started

AbCellera Biologics Inc. ABCL Cash Cash Equivalents And Short Term Investments

Cash Cash Equivalents And Short Term Investments at other companies

Precigen logo
PrecigenPGEN
——
Roivant Sciences logo
Roivant SciencesROIV
——

Other financials

Income statement

See full
Revenue$8.3M+96.3%
Operating income-$57.5M+8.2%
Net income-$43.2M+5.4%
EPS (diluted)-$0.14+6.7%

Balance sheet

See full
Cash & equivalents$102.1M-44.6%
Total debt$140.2M+107%
Total equity$938.1M-8.3%
Total assets$1.3B-2.8%

Cash flow

See full
Operating cash flow-$33.5M-190%
CapEx$3.8M-64.0%
Free cash flow-$37.4M-68.3%

Valuation

See full
Market cap$1.84B+59.2%
Enterprise value$1.88B+100.0%
P/S23.3×-26.8×

Profitability

See full
Operating margin-267.6%-120pp
Net margin-181.7%-77.9pp
FCF margin-238.9%-90.9pp

Returns & leverage

See full
Return on equity-14.7%-0.8pp
Debt / equity0.1×+0.1×
Current ratio14.1×+3.9×

Where this comes from

Reported directly by AbCellera Biologics Inc. in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsAndShortTermInvestments.

The official record: AbCellera Biologics Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about AbCellera Biologics Inc.'s cash cash equivalents and short term investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is AbCellera Biologics Inc.'s cash cash equivalents and short term investments?
AbCellera Biologics Inc. (ABCL) reported cash cash equivalents and short term investments of $504.73M in Q1 2026.
How has AbCellera Biologics Inc.'s cash cash equivalents and short term investments changed year-over-year?
AbCellera Biologics Inc.'s cash cash equivalents and short term investments decreased by 16.6% year-over-year, from $605.27M to $504.73M.
What is the long-term trend for AbCellera Biologics Inc.'s cash cash equivalents and short term investments?
Over 2 years (2023 to 2025), AbCellera Biologics Inc.'s cash cash equivalents and short term investments has grown at a -16.2% compound annual growth rate (CAGR), from $760.59M to $533.83M.